In this work, Cloupharm has been involved in the discovery of four compounds through a virtual screening procedure as putative sterol 14α-demethylase (CYP51) Candida albicans inhibitors. The compounds had the ability to inhibit growth of C. albicans cells and one was...
The Cloudpharm team participated in the 6th ENVIROMED Plenary Meeting in Kea Island, Greece in June 18-19 2025. Project progress was communicated through engagement with fellow researchers. The meeting provided an excellent opportunity to exchange ideas, discuss...
Cloudpharm announces the approval of the funded project “OSTEOME” in collaboration with the Musculoskeletal Diseases Research Laboratory “Th. Garofalidis ”of the Medical School of EKPA, the Institute of Chemical Biology of the National Research Foundation (NHRF), the...
Cloudpharm attended InnoDays 2025, connecting with fellow Greek leading researchers and innovators. The event provided an inspiring platform to exchange ideas, explore cutting-edge scientific developments, and expand our network of collaborations. These interactions...
Cloudpharm announces the approval of the funded project “Cloudscreen” in collaboration with the Institute of Chemical Biology of the National Hellenic Research Foundation (NHRF). The objective of the project is the development of a next generation “one-stop-shop”...
As of 30 November 2025, Cloudpharm and its partners have successfully completed the Horizon Europe–funded project ENVIROMED. The project represents a key contribution to the EU Green Deal, having developed innovative technologies that enable greener and more efficient...
